Loading...

PLX PROTALIX BIOTHERAPEUTICS INC US FDA Inspections 8-K Filing

PRTL

PLX

PROTALIX BIOTHERAPEUTICS INC

(PLX)

2024 8-K

Show Summary

Summary

Financial Statements

Financial Results

Bylaw Amendments

Stockholder Update

Financial Results

Clinical Trial Update

Financial Results

Annual Meeting of Stockholders

Financial Results Announcement

Financial Results Announcement

Financial Results Announcement

Annual Meeting of Stockholders

Financial Condition and Oth...

Financial Results Announcement

Agreement for Stock Sale

Financial Results Announcement

Regulation FD Disclosure

External Links:

Protalix BioTherapeutics announced that data from its phase I clinical trial of PRX-115 for uncontrolled gout will be presented at the ACR Convergence 2024 conference in November.

AI Assistant

PROTALIX BIOTHERAPEUTICS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.